QQ客服 官方微博 反馈留言

	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
	San-Miguel, Jesus F.; Hungria, Vania T. M.; Yoon, Sung-Soo; Beksac, Meral; Dimopoulos, Meletios Athanasios; Elghandour, Ashraf; Jedrzejczak, Wieslaw Wiktor; Guenther, Andreas; Nakorn, Thanyaphong Na; Siritanaratkul, Noppadol
	2014
卷号	15期号:11页码:1195-1206
ISSN号	1470-2045
DOI	10.1016/S1470-2045(14)70440-1
URL标识	查看原文
收录类别	SCIE ; PUBMED ; ESI高被引论文 ; ESI热点论文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6684886
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	San-Miguel, Jesus F.,Hungria, Vania T. M.,Yoon, Sung-Soo,et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial[J],2014,15(11):1195-1206.
APA	San-Miguel, Jesus F..,Hungria, Vania T. M..,Yoon, Sung-Soo.,Beksac, Meral.,Dimopoulos, Meletios Athanasios.,...&Richardson, Paul G..(2014).Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.,15(11),1195-1206.
MLA	San-Miguel, Jesus F.,et al."Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial".15.11(2014):1195-1206.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。